Physicians' Academy for Cardiovascular Education

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield - London, UK

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

Analogous to LDL-c, the lower the better also seems true for inflammation

3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

10' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain

Imaging components of plaque not more informative than burden of plaque

3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

L’inflammation est critique dans la prévention secondaire des évènements cardiovasculaires

5' education - Aug. 28, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

10' education - Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

3' education - Aug. 28, 2017

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

3' education - Aug. 27, 2017

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

Estimating CV risk and treatment benefit

Clinical updates in management of cardiovascular risk (4/4)

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands
Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.

Clinical updates in management of cardiovascular risk Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.

DPP-4 inhibition may reduce carotid atherosclerosis in T2DM patients in primary prevention

Literature - June 11, 2018 - Tanaka A, et al. - Int J Cardiol 2018
DPP-4 inhibition with sitagliptin for 24 months decreased the intima-media thickness of the internal carotid artery in type 2 diabetic patients without established CVD.

DPP-4 inhibition with sitagliptin for 24 months decreased the intima-media thickness of the internal carotid artery in type 2 diabetic patients without established CVD.

The role of lipids in CVD prevention: Lessons learned about statins

Clinical updates in management of cardiovascular risk (2/4)

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands
For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.

Clinical updates in management of cardiovascular risk For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.

Early intervention for lifetime CV risk reduction

Clinical updates in management of cardiovascular risk (1/4)

10' education - May 30, 2018 - Prof. John Deanfield - London, UK
CV risk factors that drive arterial disease in early life have a major impact on future CV risk. Communication about early lifestyle intervention to the public should be a major focus to reduce CV risk in later years.

Clinical updates in management of cardiovascular risk CV risk factors that drive arterial disease in early life have a major impact on future CV risk. Communication about early lifestyle intervention to the public should be a major focus to reduce CV risk in later years.

Healthy food intake and high cardiorespiratory fitness both important to slow progression of CAC

Literature - May 16, 2018 - Gripeteg L et al. - Am J Cardiol 2018

Healthy food intake was associated with having no coronary artery calcium, and in combination with higher cardiorespiratory fitness, it was also associated with lower CAC levels.

Folic acid treatment reduces the risk of stroke in hypertensive patients

Literature - May 16, 2018 - Kong X et al. - J Am Coll Cardiol 2018
Patients with hypertension with low platelet counts and high total homocysteine levels, which may promote platelet adherence, had the highest risk of first stroke, and this risk was reduced with folic acid treatment.

Patients with hypertension with low platelet counts and high total homocysteine levels, which may promote platelet adherence, had the highest risk of first stroke, and this risk was reduced with folic acid treatment.

More peripheral artery disease patients would benefit from statin therapy

Literature - Apr. 10, 2018 - Arya S et al. - Circulation. 2018
In a large community-based database, in patients with peripheral artery disease, statin therapy was associated with a significant reduction of amputations and mortality compared with no statin use.

In a large community-based database, in patients with peripheral artery disease, statin therapy was associated with a significant reduction of amputations and mortality compared with no statin use.

Fecal microbiota transplantation of vegan donor did not lower arterial wall inflammation

Literature - Apr. 3, 2018 - Smits LP et al. - J Am Heart Assoc. 2018

In a double-blind pilot study, a single lean vegan-donor fecal microbiota transplantation in obese male patients with metabolic syndrome did not alter markers of arterial wall inflammation.

Differential effect of LDL- and HDL-levels on small and large vessel disease and stroke type

Literature - Mar. 29, 2018 - Hindy G et al. - Stroke. 2018
Mendelian randomization study suggests that lowering LDL affects large artery atherosclerosis, but not small artery occlusion or cardioembolic stroke, while increasing HDL may benefit small artery disease.

Mendelian randomization study suggests that lowering LDL affects large artery atherosclerosis, but not small artery occlusion or cardioembolic stroke, while increasing HDL may benefit small artery disease.

Elevated Lp(a) associated with higher CAC score in individuals with family history of ASCVD

Literature - Feb. 26, 2018 - Verweij SL, et al. - J Clin Lipidol 2018

In young asymptomatic individuals with family history of premature ASCVD, elevated Lp(a) is related to higher CAC score, resulting in the identification of individuals with subclinical atherosclerosis.

PCSK9 inhibitor changes levels and sizes of lipoprotein particles

Literature - Jan. 23, 2018 - Toth PP et al. - Am J Cardiol 2018
Evolocumab significantly changes lipoprotein particle number and size, irrespective of concordance with LDL-c at baseline or disease status.

Evolocumab significantly changes lipoprotein particle number and size, irrespective of concordance with LDL-c at baseline or disease status.

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands
Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.

Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.